AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Janux Therapeutics' Chief Business Officer, Meyer Andrew Hollman, exercised 16,665 options and sold the resulting shares for approximately $501,000 on October 28, 2025. This sale accounted for 16.87% of Hollman's direct holdings and was a routine "exercise-and-sell" maneuver to cover tax liabilities on the gain. The transaction did not increase Hollman's net equity stake in the company.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet